Both in Pharmaceuticals
ArriVent BioPharma vs Kura Oncology
Over the past year AVBP returned +16.1% and KURA returned +5.6%; their daily moves had a correlation of 0.25.
AVBP +16.1% KURA +5.6%Growth of $1, one year, split-adjusted
| Metric | AVBP | KURA |
|---|---|---|
| Price | $19.20 | $9.49 |
| Market cap | $946.7M | $843.8M |
| Today | 0.00% | −3.80% |
| 1 month | −36.2% | −12.7% |
| 6 months | −36.9% | +2.4% |
| Year to date | −4.6% | −8.7% |
| 1 year | +3.8% | +2.2% |
| Revenue growth (YoY) | — | +36.5% |
| Gross margin | — | 98.8% |
| Net margin | — | −327.3% |
| P/E (TTM) | — | — |
| Price / sales | — | 10.9× |
| Net cash | $373.1M | $509.2M |
| Dividend yield | — | — |
| Volatility (60d) | 138.7% | 54.0% |
| Short % of float | 25.2% | 18.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).